Cargando…
Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease
BACKGROUND: Sickle cell disease (SCD) is an inherited hematological disorder where the shape of red blood cells is altered, resulting in the destruction of red blood cells, anemia, and other complications. SCD is prevalent in the southern and eastern provinces of the Arabian peninsula. The most comm...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537144/ https://www.ncbi.nlm.nih.gov/pubmed/31133061 http://dx.doi.org/10.1186/s13063-019-3394-4 |
_version_ | 1783421934295318528 |
---|---|
author | Alshahrani, Mohammed S. Asonto, Laila Perlas El Tahan, Mohamed M. Al Sulaibikh, Amal H. Al Faraj, Sukayna Z. Al Mulhim, Abdullah A. Al Abbad, Murad F. Al Nahhash, Samar A. Aldarweesh, Moath N. Mahmoud, Alaa M. Almaghraby, Nisreen Al Jumaan, Mohammed A. Al Junaid, Thamir O. Al Hawaj, Faisal M. AlKenany, Samar ElSayed, Omaima F. Abdelwahab, Haitham M. Moussa, Mohamed M. Alossaimi, Bader K. Alotaibi, Shaikah K. AlMutairi, Talal M. AlSulaiman, Duaa A. Al Shahrani, Saad D. Alfaraj, Donia Alhazzani, Waleed |
author_facet | Alshahrani, Mohammed S. Asonto, Laila Perlas El Tahan, Mohamed M. Al Sulaibikh, Amal H. Al Faraj, Sukayna Z. Al Mulhim, Abdullah A. Al Abbad, Murad F. Al Nahhash, Samar A. Aldarweesh, Moath N. Mahmoud, Alaa M. Almaghraby, Nisreen Al Jumaan, Mohammed A. Al Junaid, Thamir O. Al Hawaj, Faisal M. AlKenany, Samar ElSayed, Omaima F. Abdelwahab, Haitham M. Moussa, Mohamed M. Alossaimi, Bader K. Alotaibi, Shaikah K. AlMutairi, Talal M. AlSulaiman, Duaa A. Al Shahrani, Saad D. Alfaraj, Donia Alhazzani, Waleed |
author_sort | Alshahrani, Mohammed S. |
collection | PubMed |
description | BACKGROUND: Sickle cell disease (SCD) is an inherited hematological disorder where the shape of red blood cells is altered, resulting in the destruction of red blood cells, anemia, and other complications. SCD is prevalent in the southern and eastern provinces of the Arabian peninsula. The most common complications for individuals with SCD are acute painful episodes that require several doses of intravenous opioids, making pain control for these individuals challenging. Instead of opioids, some studies have suggested that ketamine might be used for pain control in acute pain episodes of individuals with SCD. This study aims to evaluate whether the addition of ketamine to morphine can achieve better pain control, decreasing the number of repeated doses of opiates. We hypothesize that early administration of ketamine would lead to a more rapid improvement in pain score and lower opioid requirements. METHODS AND ANALYSIS: This study will be a prospective, randomized, concealed, blinded, pragmatic parallel group, controlled trial enrolling adult patients with SCD and acute vaso-occlusive crisis pain. All patients will receive standard analgesic therapy during evaluation. Patients randomized to the treatment arm will receive low-dose ketamine (0.3 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration, while those in the control group will receive a standard dose of morphine (0.1 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to the standard intravenous hydration. All healthcare providers will be blinded to the treatment arm. Data will be analyzed according to the intention-to-treat principle. The primary outcome is improvement in pain severity using the Numerical Pain Rating Score. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03431285. Registered on 13 February 2018 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3394-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6537144 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-65371442019-05-30 Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease Alshahrani, Mohammed S. Asonto, Laila Perlas El Tahan, Mohamed M. Al Sulaibikh, Amal H. Al Faraj, Sukayna Z. Al Mulhim, Abdullah A. Al Abbad, Murad F. Al Nahhash, Samar A. Aldarweesh, Moath N. Mahmoud, Alaa M. Almaghraby, Nisreen Al Jumaan, Mohammed A. Al Junaid, Thamir O. Al Hawaj, Faisal M. AlKenany, Samar ElSayed, Omaima F. Abdelwahab, Haitham M. Moussa, Mohamed M. Alossaimi, Bader K. Alotaibi, Shaikah K. AlMutairi, Talal M. AlSulaiman, Duaa A. Al Shahrani, Saad D. Alfaraj, Donia Alhazzani, Waleed Trials Study Protocol BACKGROUND: Sickle cell disease (SCD) is an inherited hematological disorder where the shape of red blood cells is altered, resulting in the destruction of red blood cells, anemia, and other complications. SCD is prevalent in the southern and eastern provinces of the Arabian peninsula. The most common complications for individuals with SCD are acute painful episodes that require several doses of intravenous opioids, making pain control for these individuals challenging. Instead of opioids, some studies have suggested that ketamine might be used for pain control in acute pain episodes of individuals with SCD. This study aims to evaluate whether the addition of ketamine to morphine can achieve better pain control, decreasing the number of repeated doses of opiates. We hypothesize that early administration of ketamine would lead to a more rapid improvement in pain score and lower opioid requirements. METHODS AND ANALYSIS: This study will be a prospective, randomized, concealed, blinded, pragmatic parallel group, controlled trial enrolling adult patients with SCD and acute vaso-occlusive crisis pain. All patients will receive standard analgesic therapy during evaluation. Patients randomized to the treatment arm will receive low-dose ketamine (0.3 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to standard intravenous hydration, while those in the control group will receive a standard dose of morphine (0.1 mg/kg in 0.9% sodium chloride, 100 ml bag) in addition to the standard intravenous hydration. All healthcare providers will be blinded to the treatment arm. Data will be analyzed according to the intention-to-treat principle. The primary outcome is improvement in pain severity using the Numerical Pain Rating Score. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03431285. Registered on 13 February 2018 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-019-3394-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-27 /pmc/articles/PMC6537144/ /pubmed/31133061 http://dx.doi.org/10.1186/s13063-019-3394-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Alshahrani, Mohammed S. Asonto, Laila Perlas El Tahan, Mohamed M. Al Sulaibikh, Amal H. Al Faraj, Sukayna Z. Al Mulhim, Abdullah A. Al Abbad, Murad F. Al Nahhash, Samar A. Aldarweesh, Moath N. Mahmoud, Alaa M. Almaghraby, Nisreen Al Jumaan, Mohammed A. Al Junaid, Thamir O. Al Hawaj, Faisal M. AlKenany, Samar ElSayed, Omaima F. Abdelwahab, Haitham M. Moussa, Mohamed M. Alossaimi, Bader K. Alotaibi, Shaikah K. AlMutairi, Talal M. AlSulaiman, Duaa A. Al Shahrani, Saad D. Alfaraj, Donia Alhazzani, Waleed Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title | Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title_full | Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title_fullStr | Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title_full_unstemmed | Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title_short | Study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
title_sort | study protocol for a randomized, blinded, controlled trial of ketamine for acute painful crisis of sickle cell disease |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6537144/ https://www.ncbi.nlm.nih.gov/pubmed/31133061 http://dx.doi.org/10.1186/s13063-019-3394-4 |
work_keys_str_mv | AT alshahranimohammeds studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT asontolailaperlas studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT eltahanmohamedm studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alsulaibikhamalh studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alfarajsukaynaz studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT almulhimabdullaha studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alabbadmuradf studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alnahhashsamara studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT aldarweeshmoathn studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT mahmoudalaam studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT almaghrabynisreen studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT aljumaanmohammeda studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT aljunaidthamiro studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alhawajfaisalm studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alkenanysamar studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT elsayedomaimaf studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT abdelwahabhaithamm studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT moussamohamedm studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alossaimibaderk studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alotaibishaikahk studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT almutairitalalm studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alsulaimanduaaa studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alshahranisaadd studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alfarajdonia studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease AT alhazzaniwaleed studyprotocolforarandomizedblindedcontrolledtrialofketamineforacutepainfulcrisisofsicklecelldisease |